Pricing systems in US drug supply chain have many limitations; an analytics-based method might avoid some of them
Marianne Messer, Elsevier's Gold Standard
Advertisement
Articles by Marianne Messer, Elsevier's Gold Standard
Advertisement
Latest Updated Articles
- Analyzing drug-pricing mechanisms
Published: October 30th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues
2
Why Regulatory Sandboxes Offer a Safe Space for AI Innovation in Healthcare
3
Pharma Pulse: CDC Layoffs Raise Public Health Concerns as Ypsomed and Lupin Expand US Manufacturing Footprint
4
Pharma Pulse: Mark Cuban Disrupts Drug Pricing, AstraZeneca Expands US Manufacturing, and BMS Bets Big on RNA Therapeutics
5
